VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SNOASonoma Pharmaceuticals, Inc.
$1.12$2M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksSNOACash Flow

Sonoma Pharmaceuticals, Inc. (SNOA) Cash Flow Statement

22Y historyFree accessUpdated daily

Free cash flow remains deeply negative, with a 2026Q1 margin of -52.8%, indicating that the company is unable to fund its operations through internal cash generation despite recent revenue gains.

SNOA Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05
Cash from Operations-3.93M-88K-2.4M-6.15M-4.25M-3.38M-4.59M-11.72M-12.44M-8.17M-8.75M-6.69M-4.89M1.15M-4.03M-4.43M-6.64M-16.83M-17.45M-18.08M-20.52M-13.53M
Operating CF Margin %-20.14%-0.62%-18.83%-46.35%-33.64%-18.13%-25.61%-61.77%-74.67%-63.68%-93.35%-48.32%-35.78%7.44%-31.64%-45.41%-90.15%-312.4%-454.92%-398.02%-794.12%-998.01%
Operating CF Growth %-4369.32%96.33%61.02%-44.82%-25.75%26.42%60.82%5.8%-52.31%6.62%-30.65%-36.89%-525.22%128.52%8.96%33.29%60.56%3.52%3.52%11.88%-51.63%-
Net Income-3.17M-3.46M-4.83M-5.15M-5.09M-3.95M-3.31M-11.8M-14.33M9.27M-10.16M-8.2M3.73M-5.43M-7.33M-7.95M-8.23M-17.66M-20.34M-19.78M-21.12M-16.53M
Depreciation & Amortization139K138K176K125K186K227K312K453K490K248K244K253K284K268K326K395K433K768K740K672K651K434K
Stock-Based Compensation255K224K516K669K382K371K839K1.64M2.41M2.15M2.34M1.77M1.45M1.6M2.8M2.37M1.43M2.26M01.58M00
Deferred Taxes-231K357K-109K-37K-829K-1.41M00651K-4.27M00-10.89M963K7.36M155K72K299K0-1.58M00
Other Non-Cash Items-515K174K161K106K-2.03M4K-773K-741K90K-15.31M493K1.67M863K624K-7.1M139K394K372K-441K1.72M-87K2.48M
Working Capital Changes-406K2.48M1.69M-1.86M3.13M1.38M-1.66M-1.27M-1.75M-257K-1.66M-2.18M-332K3.13M-83K464K-738K-2.88M2.59M-693K34K81K
Change in Receivables-122K434K-230K62K1.97M2.61M-2.19M-1.16M11K34K-1.28M40K-88K411K-164K-626K-453K-379K0-287K00
Change in Inventory-465K-388K184K44K-100K-65K323K-779K-583K-675K-382K-627K-126K-103K-309K-245K-388K-177K-180K53K551K-748K
Change in Payables871K416K-278K-864K-157K-796K336K5K9K-58K429K222K848K-10K158K-266K-163K-1.33M0-245K00
Cash from Investing-192K-80K-2K-258K-99K388K3.64M-131K-201K18.22M4.19M875K-445K-370K-360K-164K-184K-424K-617K-877K-1.58M-1.12M
Capital Expenditures-192K-80K-17K-269K-137K-179K-206K-100K-187K-394K-345K-139K-504K-257K-336K-174K-141K-393K-617K-873K-475K-1.04M
CapEx % of Revenue0.98%0.56%0.13%2.03%1.08%0.96%1.15%0.53%1.12%3.07%3.68%1%3.69%1.66%2.64%1.78%1.91%7.29%16.09%19.22%18.38%76.84%
Acquisitions0000002.7M0018.64M000000000000
Investments----------------------
Other Investing0015K11K38K567K1.15M-31K-14K-21K-2K51K59K-113K-24K10K-43K-31K0-4K-1.11M-76K
Cash from Financing477K3.03M1.68M2.49M7.4M3.31M1.03M5.49M5.24M-32K6.04M6.61M2.94M3.75M3.45M2.68M11.08M376K17.83M30.57M26.12M17.2M
Debt Issued (Net)-271K-404K-481K-894K-374K1.02M-347K-478K-280K-130K-119K-176K-1.61M-2.08M1.34M2.59M-294K-2.14M-4.11M5.31M-727K500K
Equity Issued (Net)471K3.08M1.78M2.87M7.55M2.29M1.38M5.97M5.47M06.14M6.79M3.19M5.85M1.89M94K11.38M2.51M21.94M24.86M27.32M16.7M
Dividends Paid0000000000000000000000
Share Repurchases0-1K00000000000000000000
Other Financing277K356K373K515K216K00052K98K14K01.37M-16K219K0000401K-478K0
Net Change in Cash-2.98M2.25M-692K-3.58M3.18M529K2K-6.38M-7.39M9.99M1.33M656K-2.42M4.55M-1.02M-1.89M4.34M-16.9M-227K11.6M4.16M2.42M
Free Cash Flow-4.13M-168K-2.42M-6.42M-4.38M-3.56M-4.8M-11.82M-12.63M-8.56M-9.09M-6.83M-5.39M893K-4.37M-4.6M-6.78M-17.23M-18.06M-18.95M-21M-14.57M
FCF Margin %-21.12%-1.18%-18.96%-48.38%-34.72%-19.09%-26.76%-62.29%-75.8%-66.75%-97.03%-49.32%-39.46%5.78%-34.27%-47.19%-92.07%-319.69%-471%-417.24%-812.5%-1074.85%
FCF Growth %-2355.36%93.04%62.39%-46.43%-23.28%25.85%59.41%6.41%-47.48%5.83%-33.05%-26.68%-704.03%120.44%5.11%32.11%60.64%4.64%4.71%9.72%-44.05%-
FCF per Share-2.45-0.14-2.66-18.92-16.53-17.82-32.48-127.89-250.85-182.41-105.40-108.34-169.5380.74-234.71-271.42-419.89-1399.27-4467.18-10959.66-7967.74-5738.19
FCF Conversion (FCF/Net Income)1.24x0.03x0.50x1.19x0.84x0.86x1.39x0.99x0.87x-0.88x0.86x0.82x-1.31x-0.21x0.55x0.56x0.81x0.95x0.86x0.91x0.89x0.82x
Interest Paid011K0024K12K16K000000000000000
Taxes Paid0000767K941K0000000000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and dilution risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q4)

Earnings Quality Masked by Accruals

Based on the provided quarterly data, the relationship between net income and operating cash flow is highly inconsistent, with OCF/NI ratios fluctuating wildly from 0.18 to 1.62, suggesting that reported earnings are frequently decoupled from actual cash generation due to significant working capital volatility.

The wide variance in the conversion ratio indicates that Sonoma's cash flow is heavily influenced by timing differences in receivables and payables rather than core operational efficiency. Investors should monitor whether this instability reflects genuine business cycle fluctuations or an underlying difficulty in converting sales into realized cash.

Persistent Free Cash Flow Deficits

As reported in financial statements, Sonoma's free cash flow trajectory remains deeply negative, with FCF margins reaching as low as -52.8% in 2026Q1, highlighting a structural inability to fund operations through internal cash generation despite recent top-line growth trends observed across the last ten quarters.

The consistent failure to achieve positive free cash flow suggests that the company's current business model is not yet self-sustaining. This persistent cash burn necessitates ongoing external financing, which may continue to dilute existing shareholders if management cannot bridge the gap between revenue scaling and operational profitability.

Working Capital Volatility Drives Cash

According to recent SEC filings, working capital changes have been the primary driver of cash flow variability, with swings as large as $1.5 million in a single quarter, indicating that the company's cash position is highly sensitive to the timing of distributor payments and inventory management.

The reliance on working capital shifts to bolster cash flow suggests that the company may be pulling forward or delaying payments to manage liquidity. This behavior warrants further investigation into the sustainability of these payment terms and whether they mask underlying weaknesses in the core cash conversion cycle.

SBC and Capitalized Cost Obfuscation

Analysis of the cash flow statement reveals that stock-based compensation adjustments, reaching $135,000 in 2026Q4, frequently offset operating losses, potentially obscuring the true economic cost of talent retention and the actual cash-basis burn rate experienced by the company over the last two and a half years.

By adding back non-cash expenses like stock-based compensation, the company presents a more favorable cash flow picture than the underlying operational performance warrants. Investors should focus on the unadjusted cash burn to better understand the true capital requirements needed to sustain the current commercial strategy.

SNOA — Frequently Asked Questions

Quick answers to the most common questions about buying SNOA stock.

How much cash does Sonoma Pharmaceuticals, Inc. (SNOA) generate from operations?

Sonoma Pharmaceuticals, Inc. (SNOA) generated $-3.9M in net cash from operating activities in 2026. This reflects the cash generated directly from core business operations.

What is Sonoma Pharmaceuticals, Inc.'s free cash flow?

Sonoma Pharmaceuticals, Inc. (SNOA) reported negative free cash flow of $4.1M in 2026, indicating capital requirements exceeded cash from operations.

What is Sonoma Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

Sonoma Pharmaceuticals, Inc. (SNOA) spent $0.2M on capital expenditures in 2026. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.